In an op-ed, a blogger for AARP outlines the possible harmful effects trade deals like the Trans-Pacific Partnership (TPP) may have on lower-cost generic medications.
“One of AARP’s main objections centers on the intellectual property provisions in the draft TPP agreement. These provisions would restrict prescription drug competition and result in delaying consumers’ access to lower-cost generic drugs.”
TPP negotiators are in Atlanta expecting to conclude final talks for the 12-nation trade deal.
Click here to read more.